

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_76882
Title of the Manuscript:	Seroprevalence of anti-SARS-cov-2 antibodies in covid-19 patients in Hyderabad, Pakistan
Type of the Article	Original Research Article

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

### **PART 1:** Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<ul style="list-style-type: none"><li>• Please, write in the same form the terms SARS-CoV-2 and COVID-19 in the title, text, tables, and figure. (E.g.: Title: SARS-cov-2, covid-19; Abstract: SARS-COV)</li><li>• Figure 1. Spelling mistakes, no description of the figure, caption colors not corresponding to a graphic. Observe the format assigned by the journal for graphs and tables.</li><li>• "...with other coronaviruses, usually causing the type of flu in the population...". Flu is caused by influenza viruses, not by coronaviruses.</li><li>• The objective is described in materials and methods. "Our goal was to deliver a nationwide estimation of SARS-CoV-2 exposure during the first wave of COVID-19 in the United States, with stratification by country, age, sex, race, and ethnicity, from July 2020 to July 2021." And is different from that objective found in the introduction: "In this report, we present data on the characteristics of patients with reported COVID-19 infection from various hospitals in Hyderabad, with the aim of determining the proportion of serious cases versus asymptomatic, moderate, or non-pneumonia cases."</li><li>• Material and Methods: Information about the collection period, inclusion and exclusion criteria and information on approval by the ethics committee was not found.</li></ul>	<p>Same form of SARS-CoV-2 and COVID-19 incorporated in the manuscript including figure and tables.</p> <p>The figure titles and legends are included in the manuscript as instructed.</p> <p>This section is irrelevant and deleted from the manuscript as per suggestion.</p> <p>The information about the collection period, inclusion and exclusion criteria is included in the material and method. The study is approved by the ethical committee of Isra University which is also provided in the section of ethical approval and consent to participate.</p>
<b><u>Minor</u></b> REVISION comments	<ul style="list-style-type: none"><li>• What is MR race? Please, describe in the text.</li><li>• What is MR code? Please, describe in the text.</li></ul>	<p>When the specimen is collected MR code is mentioned on the sample. This is not required to add to the manuscript because for this reason it was deleted from the manuscript.</p>
<b><u>Optional/General</u></b> comments	<p>Please, make a careful review of language, including punctuation marks, upper and lowercase letters.</p>	<p>English language of the manuscript now revised by a language expert.</p>

Review Form 1.6

PART 2:

	<b>Reviewer’s comment</b>	<b>Author’s comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<u><i>(If yes, Kindly please write down the ethical issues here in details)</i></u>  No. Despite information about the approval by the ethics committee was not found.	There is not any ethical issues in this manuscript and the study is approved by ethical committee of Isra University which is also provided in the section of ethical approval and consent to participate.